Parameter Set Antidepressants 1/EXTENDED - LC-MS/MS

Order No.: 92913/XT
Parameters:
Citalopram, Desmethylfluoxetine, Duloxetine, Fluoxetine, Fluvoxamine, Mirtazapine, N-Desmethylcitalopram, N-Desmethylmirtazapine, N-Desmethylsertraline, O-Desmethylvenlafaxine, Paroxetine, Sertraline, Venlafaxine

Encompasses 13 analytes
3PLUS1® Multilevel Calibrator Set available
Part of the MassTox® TDM Series A

CE-IVD validated product ready for IVDR within timeframes and transition periods specified by the IVDR 2017/746

Citalopram

N-Desmethylcitalopram

Duloxetine

Fluoxetine

Desmethylfluoxetine

Fluvoxamine

Mirtazapine

N-Desmethylmirtazapine

Paroxetine

Sertraline

N-Desmethylsertraline

Venlafaxine

O-Desmethylvenlafaxine

Clinical relevance

There are many drugs available for the treatment of depression. In addition to classic tricyclic antidepressant drugs, there are newer generation antidepressants: "selective serotonin re-uptake inhibitors" (SSRIs) and "selective serotonin and noradrenalin re-uptake inhibitors" (SSNRIs).

SSRIs inhibit the re-uptake of the messenger substance serotonin into the presynaptic neurons. They possess characteristics that reduce anxiety and improve mood. Usually, these positive effects start to set in about two to three weeks after starting therapy. SSNRIs are mood and motivation enhancing and act similarly to the SSRIs, but additionally block the re-uptake of noradrenalin.

Since SSRIs and SSNRIs work selectively, side effects are rare. But still, therapeutic drug monitoring is recommended, because the therapeutic endpoint is difficult to determine, and monitoring patient compliance increases the likelihood of treatment success.

 

Product advantages

With the Parameter Set Antidepressants 1/EXTENDED in serum/plasma, 13 different analytes can be measured fast and efficiently using LC-MS/MS. Due to the careful optimisation of all kit components as well as the chromatographic separation, matrix effects (“ion suppression”) are minimised and the robustness of the method is enhanced. Sample preparation is based on a protein precipitation step. The use of stable isotopically labelled (deuterated) and co-eluting internal standards as well as 3PLUS1® multilevel calibrators ensures high precision and the reproducible and reliable quantification of the analytes. The method is comprehensively validated.

The Parameter Set is a part of the Series A modular system, which enables the analysis of all parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory. The Basic Kit A contains all components required for sample preparation and all necessary mobile phases. The MasterColumn® A is the analytical column used for the determination of all Series A analytes. Our portfolio contains further MassTox® Parameter Sets.

For the analysis you require the MassTox® TDM Basic Kit A, the specific MassTox® TDM Parameter Set and the analytical column MassTox® TDM MasterColumn® A.

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation 0.5 – 30.0 µg/l
Upper Limit of Quantification at least twice the therapeutic range
Intraassay CV < 9 %
Interassay CV < 9 %
Specimen Serum/Plasma
Sample Preparation
  • Reconstitute the Internal Standard Mix.
  • Add 800 μl Internal Standard Mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 μl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 μl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 μl of mixture A and mix 30 s minimum (vortex) and centrifuge 5 min.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity
Run Time 3.0 min
Injection Volume 0.2 – 50 µl
Gradient

0.00-0.20 min    0 % Mobile Phase 2
0.21-0.70 min    50 % Mobile Phase 2
0.71-2.40 min    80 % Mobile Phase 2
2.41-3.00 min    0 % Mobile Phase 2

Ionisation ESI positive
MS/MS Mode MRM
Additional Info We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.
Parameters Citalopram, Desmethylfluoxetine, Duloxetine, Fluoxetine, Fluvoxamine, Mirtazapine, N-Desmethylcitalopram, N-Desmethylmirtazapine, N-Desmethylsertraline, O-Desmethylvenlafaxine, Paroxetine, Sertraline, Venlafaxine
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.

Citalopram

N-Desmethylcitalopram

Duloxetine

Fluoxetine

Desmethylfluoxetine

Fluvoxamine

Mirtazapine

N-Desmethylmirtazapine

Paroxetine

Sertraline

N-Desmethylsertraline

Venlafaxine

O-Desmethylvenlafaxine

Clinical relevance

There are many drugs available for the treatment of depression. In addition to classic tricyclic antidepressant drugs, there are newer generation antidepressants: "selective serotonin re-uptake inhibitors" (SSRIs) and "selective serotonin and noradrenalin re-uptake inhibitors" (SSNRIs).

SSRIs inhibit the re-uptake of the messenger substance serotonin into the presynaptic neurons. They possess characteristics that reduce anxiety and improve mood. Usually, these positive effects start to set in about two to three weeks after starting therapy. SSNRIs are mood and motivation enhancing and act similarly to the SSRIs, but additionally block the re-uptake of noradrenalin.

Since SSRIs and SSNRIs work selectively, side effects are rare. But still, therapeutic drug monitoring is recommended, because the therapeutic endpoint is difficult to determine, and monitoring patient compliance increases the likelihood of treatment success.

 

Product advantages

With the Parameter Set Antidepressants 1/EXTENDED in serum/plasma, 13 different analytes can be measured fast and efficiently using LC-MS/MS. Due to the careful optimisation of all kit components as well as the chromatographic separation, matrix effects (“ion suppression”) are minimised and the robustness of the method is enhanced. Sample preparation is based on a protein precipitation step. The use of stable isotopically labelled (deuterated) and co-eluting internal standards as well as 3PLUS1® multilevel calibrators ensures high precision and the reproducible and reliable quantification of the analytes. The method is comprehensively validated.

The Parameter Set is a part of the Series A modular system, which enables the analysis of all parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory. The Basic Kit A contains all components required for sample preparation and all necessary mobile phases. The MasterColumn® A is the analytical column used for the determination of all Series A analytes. Our portfolio contains further MassTox® Parameter Sets.

For the analysis you require the MassTox® TDM Basic Kit A, the specific MassTox® TDM Parameter Set and the analytical column MassTox® TDM MasterColumn® A.

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation 0.5 – 30.0 µg/l
Upper Limit of Quantification at least twice the therapeutic range
Intraassay CV < 9 %
Interassay CV < 9 %
Specimen Serum/Plasma
Sample Preparation
  • Reconstitute the Internal Standard Mix.
  • Add 800 μl Internal Standard Mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 μl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 μl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 μl of mixture A and mix 30 s minimum (vortex) and centrifuge 5 min.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity
Run Time 3.0 min
Injection Volume 0.2 – 50 µl
Gradient

0.00-0.20 min    0 % Mobile Phase 2
0.21-0.70 min    50 % Mobile Phase 2
0.71-2.40 min    80 % Mobile Phase 2
2.41-3.00 min    0 % Mobile Phase 2

Ionisation ESI positive
MS/MS Mode MRM
Additional Info We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.
Parameters Citalopram, Desmethylfluoxetine, Duloxetine, Fluoxetine, Fluvoxamine, Mirtazapine, N-Desmethylcitalopram, N-Desmethylmirtazapine, N-Desmethylsertraline, O-Desmethylvenlafaxine, Paroxetine, Sertraline, Venlafaxine
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.